相关实验视频
Updated: Sep 13, 2025

05:30
Ex Vivo Hepatic Perfusion Through the Portal Vein in Mouse
Published on: March 9, 2022
9.6K
在肝切除术患者中优化利多卡因剂量:对活性代谢物的一项人口药动力学研究
Chaoqun He1,2,3, Xiaohui Qi1,3, Yixian Liu1,3
1Department of Pharmacy, NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.
Drug design, development and therapy
|July 29, 2025
概括
这项研究建议肝脏手术患者使用安全的利多卡因剂量,强调监测MEGX等活性代谢物以防止毒性. 剂量不应超过1.5毫克/公斤负载和1.5毫克/公斤/小时输液以确保患者的安全.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床药房 临床药房
- 肝胆道手术 肝胆道手术
背景情况:
- 肝功能显著影响利多卡因和活性代谢物代谢.
- 肝功能受损可能导致利多卡因及其代谢物的积累,增加毒性风险.
- 部分肝切除术患者需要仔细考虑药物代谢和剂量.
研究的目的:
- 在接受部分肝切除术的患者中描述利多卡因及其活性代谢物的群体药理动力学.
- 提出一种新的,基于模拟的药物治疗方案,用于在这个患者群体中给予利多卡因.
- 为了研究在长时间输注利多卡因期间,活性代谢物,如MEGX的积累.
主要方法:
- 对35名部分肝切除术患者的利多卡因和活性代谢物度的分析.
- 应用非线性混合效应模型来开发种群药物动力学模型.
- 剂量模拟用于评估各种利多卡因治疗方案的安全性和有效性.
主要成果:
- 一个具有第一阶淘汰的两部分模型准确地描述了利多卡因和代谢物的药理动力学.
- 推的安全剂量:中国肝切除术患者的加载剂量≤1.5 mg/kg和连续输液剂量≤1.5 mg/kg/h.
- 在输注24小时后观察到显著的MEGX积累,超过5μg/mL在1mg/kg/h.
结论:
- 第一个整合利多卡因度,活性代谢物和基于模拟的剂量建议的研究.
- 推的安全24小时剂量:加重剂量≤1.5 mg/kg,输液剂量≤1.5 mg/kg/h对于中国肝切除术患者.
- 与利多卡因一起对活性代谢物的监测对于安全的持续输液至关重要.
更多相关视频
相关概念视频
Local Anesthetics: Pharmacokinetics
852
The potency and duration of action of local anesthetics (LAs) are determined by their pharmacokinetics. Pharmacokinetics describes how LAs are absorbed, distributed, metabolized, and eliminated from the body. When administered to the vascular tissues, LAs are quickly absorbed and enter the systemic circulation, reducing their localized effects. Adding vasoconstrictors such as epinephrine to LAs reduces their absorption into the systemic circulation, making them clinically effective. The...
852
Tissue-Drug Binding: Localization of Drugs and its Significance
165
Body tissues, comprising approximately 40% of the body weight, are crucial in drug distribution and localization. These tissues can serve as drug storage sites, competing with plasma binding sites for drug molecules.
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine...
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine...
165
Hepatic Drug Clearance: Effect of Protein Binding
285
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
285

